194 related articles for article (PubMed ID: 25700663)
1. Comparison of different in vitro tests to detect Cryptococcus neoformans not susceptible to amphotericin B.
Córdoba S; Vivot W; Szusz W; Isla G; Davel G
Mycopathologia; 2015 Jun; 179(5-6):359-71. PubMed ID: 25700663
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
[TBL] [Abstract][Full Text] [Related]
3. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS.
Rodero L; Córdoba S; Cahn P; Soria M; Lucarini M; Davel G; Kaufman S; Canteros C; Guelfand L
Med Mycol; 2000 Jun; 38(3):201-7. PubMed ID: 10892987
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
5. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
Mahabeer Y; Chang CC; Naidu D; Dorasamy A; Lewin S; Ndung'u T; Moosa MY; French M; Mlisana K; Coovadia Y
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
[TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
9. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
11. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
Arechavala AI; Ochiuzzi ME; Borgnia MD; Santiso GM
Rev Iberoam Micol; 2009 Sep; 26(3):194-7. PubMed ID: 19635445
[TBL] [Abstract][Full Text] [Related]
12. Turbidimetric and visual criteria for in vitro susceptibility testing of Cryptococcus neoformans clinical isolates.
Del Poeta M; Barchiesi F; Arzeni D; Marinucci G; Scalise G
Mycoses; 1994; 37(11-12):411-6. PubMed ID: 7659128
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.
Chandenier J; Adou-Bryn KD; Douchet C; Sar B; Kombila M; Swinne D; Thérizol-Ferly M; Buisson Y; Richard-Lenoble D
Eur J Clin Microbiol Infect Dis; 2004 Jun; 23(6):506-8. PubMed ID: 15141336
[TBL] [Abstract][Full Text] [Related]
14. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Etest and Neo-Sensitabs diffusion assays on Mueller-Hinton-methylene blue agar with broth microdilution reference method (CLSI-M27-A2) for testing susceptibilities of Cryptococcus neoformans to amphotericin B and fluconazole.
Ochiuzzi ME; Santiso GM; Arechavala AI
Med Mycol; 2010 Sep; 48(6):893-6. PubMed ID: 20370370
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
Abdel-Salam HA
Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
[TBL] [Abstract][Full Text] [Related]
17. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
[TBL] [Abstract][Full Text] [Related]
18. Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?
Viviani MA; Esposto MC; Cogliati M; Tortorano AM
J Chemother; 2003 Apr; 15(2):124-8. PubMed ID: 12797387
[TBL] [Abstract][Full Text] [Related]
19. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
Klepser ME; Wolfe EJ; Pfaller MA
J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
[TBL] [Abstract][Full Text] [Related]
20. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.
Arsic Arsenijevic V; Pekmezovic MG; Meis JF; Hagen F
Mycoses; 2014 Jun; 57(6):380-7. PubMed ID: 24438323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
